Latest News

21th Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis | Call for Abstract Submission

The Israeli Society for Research, Prevention and Treatment of Atherosclerosis invites you to submit your research…

International Atherosclerosis Research School – applications opened

iARS 2016: application opened! International Atherosclerosis Research School Hamburg, Germany, from August 21st to 27th, 2016…

FH awareness week – What is FH?

September 24 is FH-awareness day. All this week, in a series of newsletters, EAS will highlight…

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Expert consensus on the rational clinical use of proprotein  convertase subtilisin/kexin type 9 (PCSK9) inhibitors Abstract Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. These fully human…

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Consensus Statement of the European Atherosclerosis Society | Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Calculation of the possibility of Familial Hypercholesterolemia using the Dutch criteria:…

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Statin-associated muscle symptoms: impacton statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management…

Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look

Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Review Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look S. Filippas-Ntekouan, M.S. Elisaf (102 – 110) Key words: nephrotic…

Is there a need for other cardiovascular risk factors besides the established risk factors?

Is there a need for other cardiovascular risk factors besides the established risk factors? HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Editorial Is there a need for other cardiovascular risk factors besides the established risk factors? K. Tziomalos…

PCSK9 Inhibitors: Research and new perspectives in clinical practice

PCSK9 Inhibitors: Research and new perspectives in clinical practice HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Review PCSK9 Inhibitors: Research and new perspectives in clinical practice E. Charatsi, I. Tsigeridis…

Familial hypercholesterolemia is undertreated in clinical practice

Familial hypercholesterolemia is undertreated in clinical practice HELLENIC JOURNAL OF ATHEROSCLEROSIS | VOLUME 7 – ISSUE 3 (JULY– SEPTEMBER 2016) Original Article Familial hypercholesterolemia is undertreated in clinical practice F. Barkas, E. Liberopoulos, G. Liamis, M. Elisaf…

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

PREFACE The American College of Cardiology (ACC) develops a number of clinical policy documents to provide members with guidance…

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This…

Joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

Joint consensus  statement from the European Atherosclerosis  Society and European Federation of Clinical  Chemistry and Laboratory Medicine

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points.…

2016 European Guidelines on cardiovascular disease prevention in clinical practice

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Published in 2016 Reference 2016 EHJ doi/10.1093/eurheartj/ehw106 The Sixth Joint Task Force of the European Society of Cardiology…

Consensus Statement of the European Atherosclerosis Society on Lipoprotein(a) as a cardiovascular risk factor

Consensus Statement of the European Atherosclerosis Society on Lipoprotein(a) as a cardiovascular risk factor

The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second,…

Consensus Statement of the European Atherosclerosis Society on Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.

Consensus Statement of the European Atherosclerosis Society on Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.

Abstract Objective: This EAS Consensus Panel critically appraised evidence relevant to the benefit to risk relationship of functional…

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).

The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in…

Photos
  • 6th Symposium of the Working Groups, 4 & 5/12/2015, Divani – Caravel, Athens

    6th Symposium of the Working Groups, 4 & 5/12/2015, Divani – Caravel, Athens

    View All

  • 23d Scientific Meeting, “Multifaceted treatment of Cardiovascular Danger” | Nafplio, Greece

    23d Scientific Meeting, “Multifaceted treatment of Cardiovascular Danger” | Nafplio, Greece

    View All

  • 24th Scientific Meeting: “Prevention and Treatment of Cardiovascular Disease” | Chalkidiki, Greece

    24th Scientific Meeting: “Prevention and Treatment of Cardiovascular Disease” | Chalkidiki, Greece

    View All

  • 2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy | Kos Greece

    2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy | Kos Greece

    View All

  • 8th Summer School (25 – 27/6/2015)

    8th Summer School (25 – 27/6/2015)

    View All